Capital Performance Advisors LLP Elevation Oncology, Inc. Transaction History
Capital Performance Advisors LLP
- $325 Million
- Q3 2024
A detailed history of Capital Performance Advisors LLP transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, Capital Performance Advisors LLP holds 11 shares of ELEV stock, worth $6. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11Holding current value
$6% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ELEV
# of Institutions
68Shares Held
45.4MCall Options Held
700Put Options Held
27.6K-
Frazier Life Sciences Management, L.P. Menlo Park, CA5.99MShares$3.42 Million0.19% of portfolio
-
Tang Capital Management LLC San Diego, CA4.76MShares$2.71 Million0.24% of portfolio
-
Goldman Sachs Group Inc New York, NY3.99MShares$2.27 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.53MShares$2.01 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.07MShares$1.75 Million0.0% of portfolio
About Elevation Oncology, Inc.
- Ticker ELEV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,300,900
- Market Cap $13.3M
- Description
- Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...